Eli Lilly will use the European Association for the Study of Diabetes 2026 meeting to detail Phase 3 retatrutide results, new Foundayo data and the first Phase 2 readout for eloraTZP, revealing how the company intends to segment an increasingly competitive obesity and diabetes market.
Foundayo became the first approved nonpeptide small-molecule GLP-1 obesity drug in 2026, replacing injectable peptide chemistry with a tablet that can be taken without food or water restrictions.
Eli Lilly and Company has created a limited expanded-access pathway for adults with severe, treatment-resistant obesity, even as regulators warn that products sold online as retatrutide are unapproved, potentially contaminated and illegal to compound.
Discover how Evidation’s 165,000-person study reveals GLP-1 growth potential, access gaps and persistence risks shaping obesity care. Read more.
Find out how Eli Lilly’s Foundayo and retatrutide data could reshape diabetes, obesity and cardiometabolic care.
Obesity drug demand is outrunning pharma capacity. Eli Lilly’s Indiana bet shows manufacturing is now a strategic moat.
Novo Nordisk has the first-mover pill. Eli Lilly has the growth aura. Oral obesity drugs are turning access into the next GLP-1 battleground.
Eli Lilly and Company’s Foundayo approval could reshape obesity treatment. Read what the oral GLP-1 launch changes for clinicians, payers, and rivals.